Tokyo, Japan and Cambridge, UK, 14 February 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the ...
The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like ...
The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like diabetes, hypertension, and aging, is driving the demand for artificial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback